Evaluating Regenxbio: Insights From 9 Financial Analysts
Evaluating Regenxbio: Insights From 9 Financial Analysts
评估Regenxbio：来自9位金融分析师的见解
During the last three months, 9 analysts shared their evaluations of Regenxbio (NASDAQ:RGNX), revealing diverse outlooks from bullish to bearish.
在过去的三个月中，9位分析师分享了他们对Regenxbio（纳斯达克股票代码：RGNX）的评估，揭示了从看涨到看跌的不同前景。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您将找到他们最近的评级摘要，揭示了过去30天中情绪的变化，并将其与前几个月进行了比较。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $40.11, a high estimate of $55.00, and a low estimate of $21.00. This current average reflects an increase of 7.25% from the previous average price target of $37.40.
分析师评估的12个月目标股价揭示了进一步的见解，平均目标价为40.11美元，最高估计为55.00美元，低估值为21.00美元。目前的平均价格比之前的平均目标价37.40美元上涨了7.25％。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析师评级：深度分析
In examining recent analyst actions, we gain...
在研究分析师最...
登录免费看全文
登录/注册